Skip to Late-Breaking Abstracts »
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
# | Title | Authors | Category | Keywords |
---|---|---|---|---|
O60 | Tumor cell-intrinsic defects in STING pathway signaling and IFN-β gene regulation | Blake Flood, BS; Leticia Corrales; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Inflammation; TLR |
O61 | Myeloid Cell-Targeted miR-146a Mimic Alleviates NF-κB-Driven Cytokine Storm without Interfering with CD19-Specific CAR T-cell Activity against B-Cell Lymphoma | Marcin Kortylewski, PhD; Yu-Lin Su; Xiuli Wang, PhD; Mati Mann; Dayson F. Moreira, PhD; Zhuoran Zhnag; Ching Ouyang; Piotr Swiderski; Stephen J. Forman, MD; David Baltimore, PhD; Ling Li; Guido Marcucci; Mark Boldin; | Immune-stimulants and immune modulators | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells |
P608 | ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer | Doreen Werchau, BS; Anna Rosen, MSc; Mia Eriksson; Sofia Järnum, PhD; Christina Furebring, PhD; Karin Enell Smith, PhD; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
P609 | Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity | Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Theodora Salcedo; Saskia Burm; Mustafa Diken; Christian Grunwitz; Danita Schuurhuis; Sebastian Kreiter; David Satijn; Özlem Türeci; Esther Breij, PhD; Ugur Sahin; Maria Jure-Kunkel; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation |
P610 | Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy | Sribalaji Lakshmikanthan, PhD; Swarna Pandian, PhD; Zusheng Li; Eugene Chan, MD; Robert Markelewicz, MD; Timothy L. Wyant, PhD; Sribalaji Lakshmikanthan, PhD; | Immune-stimulants and immune modulators | Antibody; Solid tumors; T cell; Targeted therapy |
P611 | Layer-by-Layer nanoparticles for interleukin-12 delivery | Antonio E. Barberio, BSE; Sean G. Smith, PhD; Santiago Correa; Cathy Nguyen; Paula T. Hammond; Darrell J. Irvine, PhD; Mariane Melo; Talar Tokatlian; | Immune-stimulants and immune modulators | Cytokine; Immune toxicity; Solid tumors; Tumor microenvironment |
P612 | Using a novel synthetic biology platform to generate a homogenous dipegylated IL-10 with native potency | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Yelena Pavlova; Jasmine T. Nguyen; Kristine San Jose-Galli; Gavin Hong; Lina Ma, PhD; Nicole Acuff; Taylor Ismaili, MS; Kelsea Loescher; Ingrid B. Joseph, PhD; Jill Mooney, PhD; Joseph Leveque, MD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P613 | Discovery of pharmacologically differentiated Interleukin 15 (IL-15) agonists employing a synthetic biology platform | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Robert W. Herman; Lina Ma, PhD; David B. Chen; Ingrid B. Joseph, PhD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor microenvironment |
P614 | Development of a cancer gene therapy approach based on encoding a single chain IL-12 transgene in an oncolytic T-SIGn virus vector | Sam Illingworth; Manuela Zonca; Ana Silva; Alicia Belmonte; Nalini Marino; Carla Cerqueira; Lorna Slater; Katy West; Sara Siebel; Samantha Bucktrout; Fred Ramsdell, PhD; Paul Cockle; Brian R. Champion, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P615 | Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 whilst blocking the PD-1 pathway | Laura Codarri Deak; Valeria Nicolini; Laura J. Lauener, Mrs.; Stefan Seeber, Dr.; Marine Richard; Esther Bommer; Maria Karagianni, Mrs.; Johannes Sam, Dr.; Ramona Schlenker, Dr.; Marisa Mariani, Dr.; Petra Schwalie, Dr.; Sylvia Herter, PhD; Marina Bacac, Dr.; Inja Waldhauer, Dr.; Anne Freimoser-Grundschober, Dr.; Volker Teichgräber, Dr.; Christian Klein, Dr rer nat; Pablo Umana, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; Tumor infiltrating lymphocytes (TILs) |
P616 | A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes | Feifei Cui, PhD; Lei Fang; Haijuan Gu; Yuanyuan Yang; Zhengyi Wang; Bingshi Guo; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; T cell |
P617 | Delivery of Interleukin-2 to the Acidic Tumor Microenvironment by Ultra-pH Sensitive Nanoparticles for Immunotherapy | Xinliang Ding, PhD; Jason B. Miller, PhD; Ashley Campbell; Jonathan Almazan; Tian Zhao; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
P618 | MK1169, a peptide unrelated to IL-2, is a potent IL-2Rβγc receptor agonist | William J. Dower, PhD; Steven E. Cwirla, BA; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | Cytokine; T cell |
P619 | NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models | Saul Kivimae, PhD; Takahiro Miyazaki, MS; Rhoneil Pena; Wildaliz Nieves, PhD; Andrew Moffett; Phi Quach, BS PhD; Lawrence Chinn; Marlene Hennessy, BS; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; Solid tumors |
P620 | Complementary effects of RNA encoded, extended half-life IL2 and IL7 synergize in modulating T cell responses and antitumoral efficacy. | Lena M. Kranz; Lena M. Kranz; Mathias Vormehr, PhD; Jan Dieckmann, PhD; Claudia Lindemann; David Eisel; Alexander Muik, PhD; Sina Fellermeier-Kopf; Friederike Gieseke; Bodo Tillmann; Sonja Witzel; Marlen Lepper; Mustafa Diken; Sebastian Kreiter, MD; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; T cell; Vaccine |
P621 | Nanoparticle-mediated Tumor Cell Expression of mIL-12 via Systemic Gene Delivery Treats Syngeneic Models of Murine Lung Cancers | Hye-Hyun Ahn, PhD; Christine Carrington; Heng-wen Liu; Yizong Hu; Christy Ng; Hwanhee Nam; Andrew Park; Catherine Stace; Will West, PhD; Hai-Quan Mao, PhD; Martin Pomper, MD, PhD; Chris G. Ullman, PhD; IL Minn, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Immune adjuvant; Solid tumors |
P622 | Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist | Takahiro Miyazaki, MS; Mekhala Maiti, PhD; Sara Sheibani; Joanna Wilczek; Olga Zemska; Peiwen Kuo, PhD; Saul Kivimäe; Marlene Hennessy, BS; Phi Quach, BS PhD; Ping Zhang, MS PhD; Thomas Chang, PhD; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
P623 | Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity. | Alexander Pieper, BS.; Alexander L. Rakhmilevich, MD, PhD; Dan Spiegelman; Ravi Patel, MD, PhD; Claire Baniel; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Deborah Charych, PhD; Willem W. Overwijk, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Radiotherapy; Solid tumors; T cell; Vaccine |
P624 | Layer-by-layer nanoparticles for the non-toxic delivery of interleukin-12 to orthotopic ovarian cancer | Sean G. Smith, PhD; Antonio E. Barberio, BSE; Sean G. Smith, PhD; Darrell J. Irvine, PhD; Santiago Correa; Cathy Nguyen; Mariane Melo; Talar Tokatlian, PhD; Paula T. Hammond; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; Immune toxicity; Solid tumors |
P625 | KY1043, a novel PD-L1 IL-2 immunocytokine directed towards CD25, delivers potent anti-tumour activity in vitro and in vivo | Cassandra H. Van Krinks, PhD; Timothy Malcolm; Morgane Lecointre; Richard Brown; Hanif Ali; Hannah Craig; Dirk Zahn; Siobhan O'Leary; Lucy Hepburn; Rachael Kimber; Nikole Sandy; Alla Fane-Dremucheva; Jamie Campbell, PhD, BS; Volker Germaschewski, PhD, MSc; Stephen D. Gillies, PhD; Matthew J. McCourt, BSc; Matthew J. McCourt, BSc; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P626 | Substantial improvement of cancer immunotherapy by an RNA encoded extended half-life Interleukin-2 variant. | Mathias Vormehr, PhD; Lena M. Kranz; Alexander Muik, PhD; Sina Fellermeier-Kopf; Nadja Salomon; Jan Diekmann; Claudia Lindemann; Sonja Witzel; Marlen Lepper; Friederike Gieseke; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens; Vaccine |
P627 | Comparing the functionality of Proleukin® and Akron Interleukin-2 through an analysis of key T cell subsets | Claudia Zylberberg, PhD; John Koreth, MBBS, DPhil; Jerome Ritz, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Autoimmunity; Biomarkers; CAR T cells; Cytokine; Immune adjuvant; Immune toxicity; Regulatory T cell (Treg cell); T cell; Targeted therapy |
P628 | Inhibition of histone deacetylase enhances CD8 T-cell functionality and metabolic fitness resulting in strong anti-tumor response. | Pankaj Gaur, PhD; Vivek Verma, PhD; Rahul Nnadre; Fatmah Alolaqi; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Gene expression; Metabolism; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
P629 | Therapeutic Vascular Normalization to Promote Tumor-Associated Tertiary Lymphoid Structures | Jessica Filderman, BS; Walter J. Storkus, PhD; Jessica Filderman, BS; | Immune-stimulants and immune modulators | Angiogenesis; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P630 | Induction of antitumor immune response by selective HDAC6 inhibition | Gianluca Fossati, Dr; Chiara Ripamonti; Gianluca Caprini; Andrea Stevenazzi; Barbara Vergani; Luigi Aurisicchio; Fabio Palombo, PhD; Antonella Conforti; Christian Steinkuhler; Gianluca Fossati, Dr; | Immune-stimulants and immune modulators | Neoantigens; Solid tumors; T cell; Targeted therapy |
P631 | Immunotherapy plus gene therapy: A novel nanomedicine carrying the RB94 gene that suppresses tumor growth in non-small-cell lung cancer by inducing immunogenic cell death & modulating host immunity | Joe B. Harford, PhD; Caroline Doherty; Manish Moghe; Antonina Rait, PhD; Steven Metallo, PhD; Kathleen F. Pirollo, PhD; Esther H. Chang, PhD; Sang-Soo Kim, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
P632 | Acute myeloid leukemia induced T cell suppression can be reversed by inhibition of the MAPK pathway | Kaycee Moshofsky, BS, MCR; Kyle A. Romine, BS; Yoko Kosaka, PhD; Guanming Wu; Shannon McWeeney, PhD; Evan F. Lind, PhD; | Immune-stimulants and immune modulators | Immune suppression; Leukemia/Lymphoma; T cell; Tumor evasion; Tumor microenvironment |
P633 | BPM31510, a Metabolic Modulating Anti-Cancer Agent, Demonstrates Immune Potentiating Properties by Promoting Cytotoxic T Cells and Reversing Indices of Exhaustion and Immunosuppression | Maria-Dorothea Nastke, PhD; Maria-Dorothea Nastke, PhD; Shiva Kazerounian, PhD; Anne R. Diers, PhD; Stephane Gesta, PhD; Vivek Vishnudas, PhD; Niven R. Narain, PhD; Rangaprasad Sarangarajan, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P634 | Predicting radiation-induced immune trafficking and activation in localized prostate cancer | Simon P. Keam; Heloise Halse; ThuNgoc Nguyen; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | B cell; Immune contexture; Immune suppression; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P635 | The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors | Michael S. Oh, MD; Alex Guzner; Derek A. Wainwright, PhD; Nisha A. Mohindra, MD; Young Kwang Chae, MD; Amir Behdad; Victoria Villaflor, MD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors |
P636 | Inhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer | Patrick G. Pilie, MD; Zhe Tang; Sanghee Park; Cheng Wu; Zhenyang Dong; Timothy A. Yap, MD PhD; Paul Corn; Timothy C. Thompson; | Immune-stimulants and immune modulators | Autoimmunity; Checkpoint blockade; Costimulation; Solid tumors; Targeted therapy |
P637 | Immunomodulation of solid tumors by carbon-ion therapy versus conventional photon therapy | Catherine S. Spina, MD, PhD; Chizuru Tsuruoka; Wendy Mao; Masaaki Sunaoski; Mathew Chaimowitz; Yi Shang; Shizuko Kakinuma; Charles G. Drake, MD, PhD; Catherine S. Spina, MD, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
P638 | Integrin-mediated augmentation of antigenic immunity | Upendra K. Marathi, Ph.D; Yared Hailemichael, PhD; Nandadeva Lokugamage; Michael Schotsaert; Angela Choi; Imran Chwdhury; Nisha Garg; Adolfo Garcia-Sastre; Lionel Lewis; Siddhartha De; Peter Vanderslice, PhD; Jeffrey Actor; Darren G. Woodside, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Immune adjuvant; T cell; Vaccine |
P639 | Depth of tumor implantation predicts response to in situ vaccination in a syngeneic melanoma model - an important variable influencing response to immunotherapy | Peter M. Carlson, BS; Manasi Mohan; Mat Rodriguez; Vladimir Subbotin; Amy K. Erbe, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
P640 | Intratumoral application of the RNA-based TLR-7/-8 and RIG-I agonist CV8102 promotes a pro-inflammatory tumor microenvironment and causes a durable anti-tumor response | Michael Meister, PhD; Mohamed Habbeddine, PhD; Katja Fiedler; Johannes Lutz; Mallika Ramakrishnan; Regina Heidenreich; Michael Meister, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Chemokine; Cytokine; Gene expression; Immune adjuvant; TLR; Tumor microenvironment |
P642 | Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Robert Miller; Robert Bader; Doreen Werchau, BS; Anneli Nilsson; Lill Ljung; Adnan Deronic, PhD; Allison Chunyk; Lena Schultz; Catherine McMahan; David Bienvenue; Anna Dahlman; Sara Fritzell; Maria Askmyr; Gabriela Hernandez-Hoyos; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; T cell; Targeted therapy; Tumor antigens |
P643 | Harnessing pre-existing anti-viral immunity for tumor therapy | Cuburu Nicolas, PhD; Lukas Bialkowski; Sergio Pontejo, PhD; Rina Kim, BS; Alexander Bell; Cynthia D. Thompson; Douglas R. Lowy, MD; John Schiller, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
P644 | Collagen anchoring of intratumorally administered agonist antibodies improves efficacy and limits toxicities | Joseph R. Palmeri, BS; Karl D. Wittrup, PhD; | Immune-stimulants and immune modulators | Costimulation; Immune toxicity; Solid tumors; T cell; Tumor microenvironment |
P645 | A tumor necrosis factor alpha mimetic as anti-tumor immune adjuvant | Ketki Velankar, MS; Ngoc B. Pham, BS; Ellen S. Gawalt; Wilson Meng, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Dendritic cell; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
P646 | Reprogramming CD8 cells into metabolically fit stem cell memory with superior therapeutic activity by MEK1/2 manipulation. | Vivek Verma, PhD; Pankaj Gaur, PhD; Jose Lopez; Fatmah Alolaqi; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
P647 | Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? | Praveen K. Bommareddy, MS, PhD; Samuel Rabkin, PhD; Andrew Zloza, MD, PhD; Howard L. Kaufman, MD, FACS; | Immune-stimulants and immune modulators | Biomarkers; T cell; Tumor microenvironment |
P648 | Therapeutic efficacy of oncolytic vaccinia virus requires infection and removal of deleterious host immune cells | Kristin DePeaux, BS; Greg M. Delgoffe, PhD; Saumendra Sarkar, PhD; Steve Thorne, PhD; Paolo DA. Vignali, BA; Dayana Rivadeneira, PhD; Kristin DePeaux, BS; | Immune-stimulants and immune modulators | Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P649 | Targeting Subtypes of Circulating Myeloid Cells during Oncolytic Vaccinia Virus Therapy | Tae-Ho Hwang, PhD, DDS; Bora Lee; Fen Jiang; Mong Cho, MD, PhD; Euna Cho; Tae-Ho Hwang, PhD, DDS; | Immune-stimulants and immune modulators | Immune adjuvant; Myeloid cells; Solid tumors |
P650 | Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas Induced by Oncolytic Adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Teresa Nguyen, BS; Frederick Lang, MD; Candelaria Gomez-Manzano, MD; Juan Fueyo; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
P651 | Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming | Eric Quemeneur, PharmD, PhD; Patricia Kleinpeter, MSc; Jean Baptiste Marchand, PhD; Laetitia Fend; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Immune contexture; Immune suppression; Tumor microenvironment; Vaccine |
P652 | The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity | Michael C. Warren; Sonia Das; Austin Dulak; Tauqeer H. Zaidi; Erik Devereaux; Jamie Strand; Benjamin Lee, MD PhD; Secil Koseoglu; Pamela Holland, PhD; Vito J. Palombella, PhD; Andrew C. Lake, PhD; | Immune-stimulants and immune modulators | Antibody; Dendritic cell; Immune suppression; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
P653 | Labeling method for flow cytometric analysis of radioactive tumors following immunotherapy and molecular targeted radionuclide therapy (mTRT): demonstration of augmented immune infiltrate | Peter M. Carlson, BS; Manasi Mohan; Ravi Patel, MD, PhD; Lauren Nettenstrom; Dagna Sheerar; Kathryn Fox; Mat Rodriguez; Anna Hoefges, MS; Reinier Hernandez, PhD; Chris Zahm, PhD; Douglas G. McNeel, MD, PhD; Jamey Weichert, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Immune monitoring; Radiotherapy; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
P654 | CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma | Sreedevi Danturti, PhD; Lena Sophie Mayer, MD; Sreedevi Danturti, PhD; Vesselin Tomov; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Checkpoint blockade; Chemokine; Costimulation; Cytokine; Monocyte/Macrophage; Myeloid cells; T cell; T cell lineages; Targeted therapy |
P655 | EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations | Romain Pirson, MSc; Anne Catherine Michaux; Diane Jamart; Julie Preillon, MSc.; Lucas Chaible; Chiara Martinoli, PhD; Gregory Driessens, PhD; Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
P656 | PEGylated cationic liposomal-oxaliplatin display impressive anti-cancer efficacy by dual-targeting of immunosuppressive populations and cancer-cells | Lars R. Petersen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Ragnhild G. Østrem, PhD; Kasper Kristensen, PhD; Jonas R. Henriksen, PhD; Dennis R. Elema, PhD; Andreas Kjær, MD, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor antigens; Tumor microenvironment |
P657 | Selective T cells Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor | Meir Azulay, Ph.D; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Checkpoint blockade; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
P658 | Co-delivery of synergistic immune agonists via systemic nanoparticles for interferon β-driven anti-tumor immunity and prevention of metastasis | Prabhani Atukorale; Chris J. Hoimes, MD; Prabhani Atukorale; Efstathios Karathanasis; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
P659 | ENPP1 antagonists in combination with radiation or checkpoint inhibitors demonstrate antitumor activity in syngeneic mice models of pancreatic adenocarcinoma, neuroblastoma, TNBC, and colon cancer | Lingyin Li, PhD; Mark Smith, PhD; Betty Chang, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P660 | TNF-alpha suppresses the Immunogenicity of STING-agonists | Anthony L. Desbien, PhD; Kelsey E. Sivick Gauthier; Ed Lemmens; Weiqun Liu, PhD; Brian Francica, PhD; Gabrielle L. Reiner; Charles Cho; Steven L. Bender; Jeffry M. Mckenna, DPhil; Yan Feng, PhD; Lianzing Zheng, Phd; Andrea van Elsas; Sarah McWhirter; | Immune-stimulants and immune modulators | Immune adjuvant; T cell |
P661 | Development and characterization of next generation small molecule STING agonists | Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Maciej Kujawa; Grzegorz Topolnicki; Grzegorz Cwiertnia; Aleksandra Poczkaj; Eliza Zimolag; Magdalena Mroczkowska; Agnieszka Gibas; Marcin Les; Sylwia Sudol; Marek Wronowski; Kinga Michalik; Katarzyna Banaszak; Katarzyna Wiklik; Federico Malusa; Michal Combik; Karolina Wiatrowska; Lukasz Dudek; Jose Alvarez; Anna Rajda; Maciej Rogacki; Faustyna Gajdosz; Aniela Golas; Katarzyna Wnuk-Lipinska; Ewelina Gabor-Worwa; Charles Fabritius; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Inflammation; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
P662 | Inhibiting DNA methylation can reverse epigenetic silencing of STING in melanoma and enhance antitumor T-cell activity | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez-Villarroel; Shota Aoyama, MD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Cytokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
P663 | Evaluating loss of cGAS and STING expression using a novel multiplex immunohistochemistry detection approach | Jeanette Rheinhardt; Adam Markman; Hideki Goda, PhD; Etsuko Futaya; Masaru Takahashi; Hiroyuki Yokota; Kenji Nishikawa; Hisatake Okada; Kenneth Bloom; George Abe; Joseph Krueger; Apollina Goel, PhD; | Immune-stimulants and immune modulators | Biomarkers; Immune adjuvant; Immune contexture; Tumor infiltrating lymphocytes (TILs) |
P664 | Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery | Nicole M. Haynes, PhD; Theresa Connor; Ben Morrow, PhD; Judy Doherty; Matthew Dennis, PhD; Jonathan Hubert, PhD; Sukhdeep Spall; Anthony Cuzzupe; Karen White, PhD; Susan Charman, PhD, Professor; Aaron Lock; Vicky M. Avery, PhD, Professor; Stewart Nuttall; Tom S. Peat, PhD; Olan Dolezal, PhD; Pat Pilling; Jezrael Revalde; Tin Yow; Greg Arndt; Hendrik Falk, PhD; Mark Devlin, PhD, COO; Ian P. Street, PhD; Poh S. Khoo, PhD; Paul A. Stupple, PhD; Brendon J. Monahan, PhD, CSO; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P665 | Enhancing IFN-β production through synergy between the STING and TLR pathways | Emily Higgs, BA; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Immune adjuvant; TLR |
P666 | Selective activation of antigen presenting cells by exoSTING enhances tumor antigen-specific immune response | Su Chul Jang, PhD; Kelvin Zhang; Nuruddeen Lewis, PhD; Tong Zi; Joanne Lim; Rane Harrison; Raymond J. Moniz; Katherine Kirwin; Chang Ling Sia; Christine McCoy; Kevin Dooley; Ke Xu; Jorge Sanchez-Salazar; Raymond W. Bourdeau; Agata Villiger-Oberbek; William K. Dahlberg; Shil Patel; Kyriakos Economides; Sriram Sathyanarayanan; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Gene expression; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P667 | Neoadjuvant STING agonists combined with systemic immunotherapy block metastatic recurrence in orthotopic breast tumors | Lauren Milling, BS; Darrell J. Irvine, PhD; | Immune-stimulants and immune modulators | Cytokine; Dendritic cell; Surgery; T cell; Tumor microenvironment |
P668 | TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in mice following oral or intravenous administration | Natasja Viller; Peter Dove; David Rosa; Bolette Bossen, BSc; Tran Truong; Tapfuma Mutukura; Debbie Jin; Marilyse Charbonneau; Laura Brinen; Karen Dodge; Gloria HY. Lin; Jeff Winston; Robert A. Uger; Malik Slassi; Zezhou Wang, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P669 | Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target | Jennifa Gosling, MS; Christoph W. Zapf; Ryan Rountree; Chenbo Wang; Thomas Cummins; Frederick Cohen; Hiroko Tanaka; Dahlia Weiss; Mario Cardozo; Christopher Karim; May Tan; Austin Tenn-McClellan; Szerenke Kiss von Soly; Julie Sheung; Ketki Dhamnaskar; Katherine Kurylo; Neil Bence; Arthur Sands; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
P670 | Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer | James R. Appleman, PhD; Stephen E. Webber; | Immune-stimulants and immune modulators | Chemokine; Cytokine; Dendritic cell; TLR |
P671 | Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity | Austin W. Boesch, PhD; Vasily Rybakin; Nathan Westcott; Ji Young Hwang; Kira Jørgensen; Rasmus Lassen; Martin Kraemer; Martin Bak, PhD; Gael Veiga; Jonas Bruun, PhD; Carlos Tassa; Harrison Rodts; Manny Sequeira; Glenn Leary; Santina Caruso; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Immune toxicity; MDSC; T cell; TLR; Tumor antigens; Tumor microenvironment |
P672 | Activation of CD8+ T cells in the presence of multiple TLR agonists differently affects the expression of T-cell checkpoint receptors | Donghwan Jeon, MS; Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Donghwan Jeon, MS; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; TLR |
P673 | Targeted delivery system for toll-like receptor agonists to repolarize the immunosuppressive phenotype of tumor-associated macrophages | Hyewon Ko; Soyoung Son; Sol Shin; Jae Hyung Park, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Targeted therapy; TLR; Tumor microenvironment |
P674 | In situ vaccination using a tumor-binding polymeric glyco-adjuvant for the induction of anti-tumor immunity | Tiffany Marchell; David S. Wilson; Aaron Alpar; Jeffrey Hubbell; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
P675 | Multimodal intratumoral immunotherapy potentiates complete immunologic tumor elimination of breast cancer origin diffuse liver metastases | Erik R. Soule; Jason R. Williams, MD; | Immune-stimulants and immune modulators | Antibody; Biomarkers; Checkpoint blockade; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Vaccine |
P676 | Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction | Luis A. Zuniga, PhD; Torben Leßmann; Lars Holten-Andersen; Nicola Bisek; Joachim Zettler; Sebastian Stark; Frank Faltinger; Oliver Kracker; Samuel Weisbrod; Robin Müller; Tobias Voigt; Kornelia Bigott; Mohammad A. Tabrizifard; Vibeke Breinholt; Kennett Sprogøe; Juha Punnonen; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
P677 | Warehouse approach for the development of personalized cancer vaccines by using Personal Antigen Selection Calculator (PASCal) without need for tumor biopsy | Zsolt Csiszovszki, PhD; Levente Molnár; Péter Páles; József Tóth; Orsolya Lorincz; Katalin Pántya; Eszter Somogyi; István Miklós; Wolfgang Schönharting; Sybille Urban; Tim Röhnisch; Mónika Megyesi; Eniko R. Toke; | Immune-stimulants and immune modulators | Bioinformatics; Immune adjuvant; Solid tumors; T cell; Tumor antigens; Vaccine |
P678 | Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Sanmit Adhikari; Brendan Classon, PhD; Jessica B. Flechtner, PhD; Hubert Lam, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
P679 | Scheduling androgen deprivation with AR-targeted vaccination affects anti-tumor efficacy in prostate cancer | Melissa Gamat-Huber, PhD; Douglas G. McNeel, MD, PhD; Melissa Gamat-Huber, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Vaccine |
P680 | Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy | Ray Jupp, PhD; George Kassiotis; Nicola Ternette; George Young; Duncan Howie; Fabio Marino; Matthew Davies; Hayden Selvadurai; Alvaro Sanchez; Jonathan Dodd; Laura Lozza; Elizabeth Soilleux; Peter W. Mason; Kevin Pojasek; | Immune-stimulants and immune modulators | T cell; Tumor antigens; Vaccine |
P681 | DNA Methyltransferase Inhibition Immunosensitizes Diffuse Intrinsic Pontine Gliomas to Peptide Vaccine through Augmentation of EphA2 and MHC I Expression. | Rajeev Kumar; Lauren McCarl; Alexandra Foster; Shubhanchi Nigam; Xinjuan Ma; Marissa Campagna; Alberto Broniscer; Katherine Warren; Ian Pollack; Gary Kohanbash; | Immune-stimulants and immune modulators | Pediatric tumors; Tumor antigens; Vaccine |
P682 | AI-augmented design of effective therapeutic cancer vaccines and adoptive cell therapies | Piotr Stepniak; Giovanni Mazzocco, M.Sc.; Alexander Myronov, M.Sc.; Iga Niemiec, M.Sc.; Katarzyna Gruba, M.Sc.; Piotr Skoczylas, M.Sc.; Anna Sanecka-Duin, PhD; Michal Drwal, M.Sc.; Jan Kaczmarczyk, PhD; Giovanni Mazzocco, M.Sc.; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Immune adjuvant; Neoantigens; T cell; Vaccine |
P683 | Incomplete Freund’s Adjuvant reduces Arginase, enhances a Th1 dominant cytokine environment, and supports CD40 L expression | Karlyn E. Pollack, MD; Max O. Meneveau, MD; Alexander F. Koeppel; Samuel J. Young; Stephen D. Turner; Katia Sol-Church, MD; Ileana S. Mauldin, PhD; Craig L. Slingluff, Jr., MD; | Immune-stimulants and immune modulators | Chemokine; Dendritic cell; Gene expression; Immune adjuvant; Solid tumors; T cell; TLR; Vaccine |
P684 | Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy | Guilhem Richard, PhD; Gad Berdugo, MSc, MBA; Michael F. Princiotta, MS, PhD; Leonard Moise, PhD; Matthew Ardito, BA; Christine Boyle; Dominique Bridon; William Martin, BA MD; Anne S. de Groot, MD; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy |
P685 | Inhibition of EZH2 enhances tumor immunogenicity through diversification of tumor antigen presentation | Jing Qiu, PhD; Thomas Paul; | Immune-stimulants and immune modulators | Immune suppression; Neoantigens; Vaccine |
P686 | The NCI PREVENT Program portfolio for precision cancer immunoprevention | Shizuko Sei, MD; Altaf Mohammed, PhD; Jennifer Fox, PhD; Romaine I. Fernando, PhD; Daniel Boring, RPh, PhD; Mark Miller, PhD; Robert Shoemaker, PhD; | Immune-stimulants and immune modulators | Neoantigens; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
P687 | Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours. | Vinod Sommandas; Satwinder K. Singh; Erik Manting; Satwinder K. Singh; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Vaccine |
P688 | Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth | Pratima Sinha, PhD; Matthew Ardito, BA; Guilhem Richard; Leonard Moise, PhD; Gad Berdugo, MSc, MBA; Teri Heiland; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Vaccine |
P689 | Amphiphile-modifications target mKRAS-antigen and adjuvant to lymph nodes and enable polyfunctional mKRAS-specific immune responses with potent cytolytic activity | Martin Steinbuck; Peter DeMuth, PhD; Lochana Seenappa, MS; Martin Steinbuck; | Immune-stimulants and immune modulators | Immune adjuvant; T cell; Tumor antigens; Vaccine |
P690 | Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor | Liang Deng, PhD, MD; Ning Yang; Yi Wang, MS; Peihong Dai; Stewart Shuman, MD PhD; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; Tumor antigens |
P691 | Monoclonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity | Humphrey A. Gardner, MD; Shubhra Kashyap, MS; Peter Sandy, PhD; Holly Ponichtera, PhD; Shannon Argueta, PhD; Chris Davitt, PhD; Michael Goldberg, PhD; Mark Carlson, MS; Maria Sizova, PhD; Valeria Kravitz, MS; Erin Troy, PhD; Sam Andrewes, MS; Mark Bodmer, PhD; Loise Francisco-Anderson, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; NK/NK T cell; Tumor infiltrating lymphocytes (TILs) |
P692 | Blockade of PGE2 Production and Signaling Enhances the Magnitude and Selectivity of BCG-Promoted Immune Responses in the Human Bladder Cancer Microenvironment | Omar M. Ibrahim, BPharm; Melissa Grimm, PhD; Weijan Jiang; Khurshid Guru; Gurkamal S. Chatta, MD; Pawel Kalinski, MD, PhD; | Immune-stimulants and immune modulators | Inflammation; TLR; Tumor microenvironment |
P857 | ONM-500 - A Novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy | Jason Miller, PhD, Min Luo, Hua Wang, Zhaohui Wang, Xinliang Ding, PhD, Ashley Campbell, Jonathan Almazan, Zhijian Chen, Jinming Gao, Tian Zhao | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |